Curasight Information

Curasight is founded in 2013 in Denmark based on a strong understanding of nuclear medicines and more than a decade of research at Copenhagen’s University hospital, Rigshospitalet and the University of Copenhagen, where the potential of targeting the urokinase-type plasminogen activator receptor (uPAR) in solid cancer tumors was identified. Led by Professor Andreas Kjær (CSO & Co-founder), the research demonstrated how uPAR could be used not only to visualize aggressive cancer biology through PET imaging, but also as a highly selective target for radionuclide therapy. These insights formed the basis for Curasight’s theranostic approach and the establishment of the company. Since its establishment, Curasight has focused on advancing a uPAR-based platform combining diagnostic uPAR-PET imaging (uTRACE®) and targeted radioligand therapy (uTREAT®) to identify, target, and eliminate all types of aggressive solid tumors with unmatched precision. Following its 2020 listing on Spotlight Market (~DKK 97 million raised), Curasight partnered uTRACE® with Curium in 2023 for global development and commercialization within diagnosis of prostate cancer. Through the years Curasight has conducted nine clinical trials (450 patients) with uTRACE® in eight solid cancer types, demonstrating favorable biodistribution (precision) and safety data across solid tumors. Curasight initiated its first Phase I uTREAT® clinical trial in glioblastoma in 2025.